Crypto Últimas notícias

Bitcoin (CRYPTO:BTC) reclaimed $80,000 on August 27 after breaking above $79,000 resistance.

Polish Olympic Committee president Radosław Piesiewicz was arrested during a probe into suspected financial benefits linked to Zondacrypto.

Hyperliquid Strategies raised $646.6 million and increased its Hyperliquid (CRYPTO:HYPE) holdings to 29.3 million tokens.

The UK plans to give the Bank of England a secondary role supporting payment innovation, including stablecoins.

Bithumb has won two lawsuits seeking money from users who sold Bitcoin (CRYPTO:BTC) after a mistaken credit.

HM Revenue and Customs said 240 people reported more than £1 million in crypto gains in 2024–25.

Trump Media & Technology Group has dropped Truth Predict plans and will market Crypto.com’s prediction products instead.

Padraig McDonnell, CEO of Agilent Technologies, discussed the company's recent financial performance following a quarter that saw approximately 7% organic revenue growth and an adjusted earnings per share (EPS) of $1.62. The conversation focused on the key drivers behind this growth and the factors contributing to the strong EPS figure. He speaks with Romaine Bostick & Emily Graffeo on "The Close."

Everpure reported a strong quarter with a 38% revenue increase and raised its full-year sales guidance to approximately $600 million. Chairman and CEO Charlie Giancarlo attributed growth to both higher prices and significant market share gains, including a 50% increase in core product sales and a 120% rise in its as-a-service offerings year over year. He speaks with Romaine Bostick & Emily Graffeo on "The Close."

Saira Malik, Chief Investment Officer at Nuveen, talks about what she wants to hear from Fed Chair Kevin Warsh in Jackson Hole and she explains why she's bullish on software stocks. Malik speaks on "Bloomberg The Close."

Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday. It's one of the first medicines to broadly target RAS, a protein tied to tumor growth that's mutated in most pancreatic cancers. The approval opens a new front against a disease where treatment has advanced slowly. Bloomberg's Madison Muller reports.

Jack Manley, Global Market Strategist at JPMorgan Asset Management, said that he's not expecting to get any information about the path of rates from Fed Chair Kevin Warsh's remarks in Jackson Hole. Manley said that he expects Warsh to paint inflation as the 'be all, end all' for the Fed's economic policy decisions and potentially give insight into how he is measuring that data.